John Pottage Jr. Buys 10,000 Shares of Spero Therapeutics

On June 23, 2026, John Pottage Jr. purchased 10,000 shares of Spero Therapeutics, Inc. (NasdaqGS:SPRO). This insider transaction shows continued interest in the biotechnology company, known for its focus on developing treatments for multi-drug resistant bacterial infections. Shares of Spero traded near $2.02 on Friday.

Insider Buying and Selling at Spero Therapeutics, Inc.

Several insiders at Spero Therapeutics have been actively purchasing shares. Alongside John Pottage Jr., Scott Thomas Jackson, Milind Deshpande, Cynthia Smith, Patrick V.J.J. Vink, and Frank Thomas each bought 20,000 shares on June 23, 2026. None of these transactions were part of a pre-planned 10b5-1 trading plan.

Other Institutional Activity in Spero Therapeutics

Among institutional investors, Vanguard Capital Management LLC opened a new position with 1,799,880 shares valued at about $4.21 million. Renaissance Technologies LLC reduced its holdings by 90,287 shares, now holding 1,189,235 shares worth approximately $2.78 million. Meanwhile, Two Sigma Investments, LP significantly increased its stake by 513,061 shares, ending with 885,631 shares valued at around $2.07 million.

Spero Therapeutics, Inc. Stock Up 68.3%

As of Friday, Spero Therapeutics traded near $2.02, with a market capitalization of approximately $117 million. The stock has a P/E ratio of 7.48 and a beta of 1.456, indicating moderate volatility. Over the past 52 weeks, Spero's stock has ranged from a low of $1.80 to a high of $3.22. Its 50-day and 200-day moving averages are $2.63 and $2.40, respectively. The company maintains a strong financial position with a current ratio of 10.50 and a quick ratio of 10.23.

Analysts Set New Price Targets

Analysts have set varying price targets for Spero Therapeutics. On January 30, 2025, HC Wainwright & Co. reiterated a 'buy' rating with a target price of $5.00. The consensus rating for the stock is 'hold', with an average target price of $4.00 based on one analyst's opinion.

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. It focuses on developing new treatments for multi-drug resistant bacterial infections and rare diseases. One of its key products is Tebipenem HBr, an oral antibiotic aimed at treating complicated urinary tract infections. The company was founded in 2013 and is led by CEO Esther P. Rajavelu.

Bottom Line

Insider buying at Spero Therapeutics suggests confidence in the company's future prospects. Investors often track such transactions for potential insights into the company's outlook. However, it's important to remember that these filings reflect past activity and may not indicate current or future trends.